Posted by Michael Wonder on 06 May 2025
Italfarmaco announces US FDA grants fast track designation to givinostat in treatment of polycythemia vera
6 May 2025 - Italfarmaco announced today that the US FDA has granted fast track designation to givinostat for the treatment of patients with polycythemia vera, a rare haematologic cancer, for which treatment options are limited.
The Phase 3 trial is currently enrolling patients with clinical sites open in Europe, the UK, Israel, and North America, with more sites expected soon.
